Meningitis Vaccine Project
http://dbpedia.org/resource/Meningitis_Vaccine_Project an entity of type: WikicatVaccination-relatedOrganizations
The Meningitis Vaccine Project is an effort to eliminate the meningitis epidemic in Sub-Saharan Africa by developing a new meningococcal vaccine. The meningitis problem in that area is caused by a strain of meningitis called "meningitis A", which is present only in the African meningitis belt. In June 2010 various sources announced that they had developed MenAfriVac, which is an inexpensive, safe, and highly effective vaccine which is likely to stop the epidemic as quickly as anyone had ever hoped that it would.
rdf:langString
Le Projet Vaccins Méningite (mieux connu sous le nom de MVP pour Meningitis Vaccine Project) est né d'une initiative de l'Organisation mondiale de la Santé (OMS) qui, à la suite de l'épidémie dévastatrice de 1996-1997 en Afrique, a décidé de mettre tout en œuvre pour développer et introduire des vaccins conjugués capables de combattre et éliminer les épidémies de méningite à méningocoques en Afrique sub-saharienne.
rdf:langString
rdf:langString
Projet Vaccins Méningite
rdf:langString
Meningitis Vaccine Project
xsd:integer
29735701
xsd:integer
1078619445
rdf:langString
The Meningitis Vaccine Project is an effort to eliminate the meningitis epidemic in Sub-Saharan Africa by developing a new meningococcal vaccine. The meningitis problem in that area is caused by a strain of meningitis called "meningitis A", which is present only in the African meningitis belt. In June 2010 various sources announced that they had developed MenAfriVac, which is an inexpensive, safe, and highly effective vaccine which is likely to stop the epidemic as quickly as anyone had ever hoped that it would. The project marked the first time that medical research had developed a vaccine to combat a disease which is endemic to and only a problem for Africa. The project began in 2001 when the Bill & Melinda Gates Foundation awarded the World Health Organization and the Program for Appropriate Technology in Health (PATH) a US $70 million seed grant to begin research.
rdf:langString
Le Projet Vaccins Méningite (mieux connu sous le nom de MVP pour Meningitis Vaccine Project) est né d'une initiative de l'Organisation mondiale de la Santé (OMS) qui, à la suite de l'épidémie dévastatrice de 1996-1997 en Afrique, a décidé de mettre tout en œuvre pour développer et introduire des vaccins conjugués capables de combattre et éliminer les épidémies de méningite à méningocoques en Afrique sub-saharienne. En 2001, la Fondation Bill-et-Melinda-Gates octroyait 70 millions USD à l'organisation non gouvernementale PATHet à l'OMS pour la création du Projet Vaccins Méningite/Meningitis Vaccine Project (MVP). La mission du MVP est d’éliminer les épidémies de méningite en tant que problème de santé publique en Afrique sub-saharienne par le développement, la mise au point, l’introduction et l’utilisation à grande échelle de vaccins conjugués contre les méningocoques.
xsd:nonNegativeInteger
4474
